Bruce C Trapnell

List of Publications by Year
in descending order

76	7,695	66343	71685
papers	citations	42 h-index	76 g-index

77	77	77	6695
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pulmonary Alveolar Proteinosis. New England Journal of Medicine, 2003, 349, 2527-2539.	27.0	713
2	GM-CSF Regulates Alveolar Macrophage Differentiation and Innate Immunity in the Lung through PU.1. Immunity, 2001, 15, 557-567.	14.3	528
3	Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet, The, 2017, 389, 1710-1718.	13.7	482
4	Diffuse Lung Disease in Young Children. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1120-1128.	5.6	443
5	Characteristics of a Large Cohort of Patients with Autoimmune Pulmonary Alveolar Proteinosis in Japan. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 752-762.	5.6	391
6	GM-CSF Regulates Pulmonary Surfactant Homeostasis and Alveolar Macrophage-Mediated Innate Host Defense. Annual Review of Physiology, 2002, 64, 775-802.	13.1	306
7	Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA . Journal of Experimental Medicine, 2008, 205, 2703-2710.	8.5	275
8	GM-CSF Autoantibodies and Neutrophil Dysfunction in Pulmonary Alveolar Proteinosis. New England Journal of Medicine, 2007, 356, 567-579.	27.0	258
9	Pulmonary macrophage transplantation therapy. Nature, 2014, 514, 450-454.	27.8	249
10	Pulmonary alveolar proteinosis. Nature Reviews Disease Primers, 2019, 5, 16.	30.5	244
11	High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood, 2003, 103, 1089-1098.	1.4	201
12	Inhaled Granulocyte/Macrophageâ€“Colony Stimulating Factor as Therapy for Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1345-1354.	5.6	184
13	Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. Journal of Leukocyte Biology, 2005, 77, 914-922.	3.3	174
14	GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatology, The, 2020, 2, e465-e473.	3.9	173
15	Hereditary Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1292-1304.	5.6	151
16	Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages. Current Opinion in Immunology, 2009, 21, 514-521.	5.5	142
17	Human GM-CSF Autoantibodies and Reproduction of Pulmonary Alveolar Proteinosis. New England Journal of Medicine, 2009, 361, 2679-2681.	27.0	134
18	Granulocyte/macrophageâ€“colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood, 2009, 113, 2547-2556.	1.4	131

#	Article	IF	Citations
19	Systemic Juvenile Idiopathic Arthritisâ€“Associated Lung Disease: Characterization and Risk Factors. Arthritis and Rheumatology, 2019, 71, 1943-1954.	5.6	124
20	GM-CSF, via PU.1, regulates alveolar macrophage FcÎ³R-mediated phagocytosis and the IL-18/IFN-Î³â€“mediated molecular connection between innate and adaptive immunity in the lung. Blood, 2002, 100, 4193-4200.	1.4	122
21	PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 285, L1132-L1136.	2.9	113
22	Pulmonary Alveolar Proteinosis Syndrome. Clinics in Chest Medicine, 2016, 37, 431-440.	2.1	113
23	Fosfomycin/Tobramycin for Inhalation in Patients with Cystic Fibrosis with Pseudomonas Airway Infection. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 171-178.	5.6	106
24	Indium Lung Disease. Chest, 2012, 141, 1512-1521.	0.8	100
25	Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. Orphanet Journal of Rare Diseases, 2016, 11, 115.	2.7	100
26	Patient-derived Granulocyte/Macrophage Colonyâ€“Stimulating Factor Autoantibodies Reproduce Pulmonary Alveolar Proteinosis in Nonhuman Primates. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 49-61.	5.6	85
27	Comparative Study of High-Resolution CT Findings Between Autoimmune and Secondary Pulmonary Alveolar Proteinosis. Chest, 2009, 136, 1348-1355.	0.8	82
28	Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. Journal of Immunological Methods, 2014, 402, 57-70.	1.4	80
29	Diffuse Lung Disease in Biopsied Children 2 to 18 Years of Age. Application of the chILD Classification Scheme. Annals of the American Thoracic Society, 2015, 12, 1498-1505.	3.2	74
30	Efficient in vivo catheter-based pericardial gene transfer mediated by adenoviral vectors. Clinical Cardiology, 1999, 22, 23-29.	1.8	73
31	Alveolar macrophage deficiency in osteopetrotic mice deficient in macrophage colony-stimulating factor is spontaneously corrected with age and associated with matrix metalloproteinase expression and emphysema. Blood, 2001, 98, 2845-2852.	1.4	71
32	Efficacy and safety of CreonÂ® 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. Journal of Cystic Fibrosis, 2009, 8, 370-377.	0.7	66
33	Clinical Significance of Interferon-Î³ Neutralizing Autoantibodies Against Disseminated Nontuberculous Mycobacterial Disease. Clinical Infectious Diseases, 2018, 66, 1239-1245.	5.8	64
34	Targeting cholesterol homeostasis in lung diseases. Scientific Reports, 2017, 7, 10211.	3.3	62
35	Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. New England Journal of Medicine, 2020, 383, 1635-1644.	27.0	61
36	Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis. Nature Communications, 2018, 9, 3127.	12.8	60

#	Article	IF	Citations
37	Endocytic Internalization of Adenovirus, Nonspecific Phagocytosis, and Cytoskeletal Organization Are Coordinately Regulated in Alveolar Macrophages by GM-CSF and PU.1. Journal of Immunology, 2002, 169, 6332-6342.	0.8	59
38	Pulmonary Transplantation of Human Induced Pluripotent Stem Cellâ€“derived Macrophages Ameliorates Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 350-360.	5.6	57
39	Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatology, The, 2021, 3, e410-e418.	3.9	57
40	Prevalence and healthcare burden of pulmonary alveolar proteinosis. Orphanet Journal of Rare Diseases, 2018, 13, 129.	2.7	54
41	Î±1-Antitrypsin Augmentation Therapy for PI*MZ Heterozygotes. Chest, 2008, 134, 831-834.	0.8	50
42	Assessment and management of pulmonary alveolar proteinosis in a reference center. Orphanet Journal of Rare Diseases, 2013, 8, 40.	2.7	49
43	Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 653-661.	0.9	49
44	Respirable indium exposures, plasma indium, and respiratory health among indiumâ€tin oxide (ITO) workers. American Journal of Industrial Medicine, 2016, 59, 522-531.	2.1	43
45	iPSC-Derived Macrophages Effectively Treat Pulmonary Alveolar Proteinosis in Csf2rb-Deficient Mice. Stem Cell Reports, 2018, 11, 696-710.	4.8	40
46	Quantitative Analysis of Longitudinal Response to Aerosolized Granulocyte-Macrophage Colony-Stimulating Factor in Two Adolescents With Autoimmune Pulmonary Alveolar Proteinosis. Chest, 2009, 135, 842-848.	0.8	36
47	Gene Therapy of Î²c-Deficient Pulmonary Alveolar Proteinosis (Î²c-PAP): Studies in a Murine in vivo Model. Molecular Therapy, 2008, 16, 757-764.	8.2	33
48	IFN-Î² Improves Sepsis-related Alveolar Macrophage Dysfunction and Postseptic Acute Respiratory Distress Syndromeâ€“related Mortality. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 45-55.	2.9	32
49	Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis. European Respiratory Journal, 2018, 51, 1702457.	6.7	31
50	Autoimmune Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1016-1035.	5.6	28
51	Efficacy and safety of PANCREAZEÂ® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. Journal of Cystic Fibrosis, 2011, 10, 350-356.	0.7	26
52	Complete Tracheal Ring Deformity. A Translational Genomics Approach to Pathogenesis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1267-1281.	5.6	25
53	Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Arthritis and Rheumatology, 2022, 74, 1271-1283.	5.6	24
54	Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency. Stem Cell Reports, 2016, 7, 292-305.	4.8	23

#	Article	IF	Citations
55	Long-Term Safety and Efficacy of Gene-Pulmonary Macrophage Transplantation Therapy of PAP in Csf2raâ^'/â^' Mice. Molecular Therapy, 2019, 27, 1597-1611.	8.2	21
56	Increased Pulmonary GM-CSF Causes Alveolar Macrophage Accumulation. Mechanistic Implications for Desquamative Interstitial Pneumonitis. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 87-94.	2.9	21
57	A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis. Chest, 2016, 150, 251-253.	0.8	20
58	A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment. BMC Medical Research Methodology, 2020, 20, 58.	3.1	20
59	Recombinant Adeno-Associated Virus Vector Genomes Take the Form of Long-Lived, Transcriptionally Competent Episomes in Human Muscle. Human Gene Therapy, 2016, 27, 32-42.	2.7	18
60	Function and Safety of Lentivirus-Mediated Gene Transfer forCSF2RA-Deficiency. Human Gene Therapy Methods, 2017, 28, 318-329.	2.1	16
61	Impaired granulocyte-macrophage colony-stimulating factor bioactivity accelerates surgical recurrence in ileal Crohnâ€™s disease. World Journal of Gastroenterology, 2018, 24, 623-630.	3.3	14
62	Blood Testing for Differential Diagnosis of Pulmonary Alveolar Proteinosis Syndrome. Chest, 2019, 155, 450-452.	0.8	13
63	A standardized blood test for the routine clinical diagnosis of impaired GM-CSF signaling using flow cytometry. Journal of Immunological Methods, 2014, 413, 1-11.	1.4	12
64	Relationship Between Diffuse Pulmonary Fibrosis, Alveolar Proteinosis, and Granulocyte-Macrophage Colony Stimulating Factor Autoantibodies. Respiratory Care, 2011, 56, 1608-1610.	1.6	11
65	Pulmonary alveolar proteinosis: An autoimmune disease lacking an HLA association. PLoS ONE, 2019, 14, e0213179.	2.5	11
66	A murine model of hereditary pulmonary alveolar proteinosis caused by homozygous Csf2ra gene disruption. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 322, L438-L448.	2.9	11
67	Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge. Advances in Experimental Medicine and Biology, 2017, 1031, 419-442.	1.6	10
68	Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy. Chronic Respiratory Disease, 2020, 17, 147997311990061.	2.4	9
69	Granulocyte Macrophage-Colony Stimulating Factor Augmentation Therapy in Sepsis. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 129-130.	5.6	9
70	Signal Transducer and Activator of Transcription 5B Deficiencyâ€“associated Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1245-1250.	5.6	8
71	Effective hematopoietic stem cell-based gene therapy in a murine model of hereditary pulmonary alveolar proteinosis. Haematologica, 2020, 105, 1147-1157.	3.5	7
72	Blood testing in the diagnosis of pulmonary alveolar proteinosis. Lancet Respiratory Medicine,the, 2018, 6, e54.	10.7	5

#	Article	IF	Citations
73	The Alveolar Lipidome in Pulmonary Alveolar Proteinosis. A New Target for Therapeutic Development?. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 800-802.	5.6	4
74	Two-year follow-up of exposure, engineering controls, respiratory protection and respiratory health among workers at an indium-tin oxide (ITO) production and reclamation facility. Occupational and Environmental Medicine, 2022, 79, 550-556.	2.8	2
75	A lymphocyte-mediated cause of secondary PAP. Blood, 2015, 125, 215-216.	1.4	1
76	Does Granulocyteâ€“Macrophage Colony-Stimulating Factor Coordinate a Hepatopulmonary Axis of Lipid Metabolism?. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 383-385.	2.9	1